Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pediatrics
Volume 2016, Article ID 7869174, 3 pages
http://dx.doi.org/10.1155/2016/7869174
Case Report

Mitochondrial Disorder Aggravated by Metoprolol

Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX, USA

Received 3 June 2016; Revised 12 September 2016; Accepted 3 October 2016

Academic Editor: Alberto Spalice

Copyright © 2016 Cheryl Samuels et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. W. Schmidt, “Unraveling environmental effects on mitochondria,” Environmental Health Perspectives, vol. 118, no. 7, pp. A292–A297, 2010. View at Publisher · View at Google Scholar
  2. M. K. Koenig, “Presentation and Diagnosis of Mitochondrial disorders in children,” Pediatric Neurology, vol. 38, no. 5, pp. 305–313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. F. P. Bernier, A. Boneh, X. Dennett, C. W. Chow, M. A. Cleary, and D. R. Thorburn, “Diagnostic criteria for respiratory chain disorders in adults and children,” Neurology, vol. 59, no. 9, pp. 1406–1411, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Arveladze, N. Geladze, N. Khachapuridze et al., “Mitochondrial dysfunction: modern aspects of therapy,” Georgian Medical News, no. 244-245, pp. 78–84, 2015. View at Google Scholar
  5. S. Parikh, A. Goldstein, M. K. Koenig et al., “Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society,” Genetics in Medicine, vol. 17, no. 9, pp. 689–701, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Finsterer and L. Segall, “Drugs interfering with mitochondrial disorders,” Drug and Chemical Toxicology, vol. 33, no. 2, pp. 138–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Scatena, P. Bottoni, G. Botta, G. E. Martorana, and B. Giardina, “The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic,” American Journal of Physiology, vol. 293, no. 1, pp. 12–21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Kishi, T. Watanabe, and K. Folkers, “Bioenergetics in clinical medicine. XV. Inhibition of coenzyme q10 enzyme by clinically adrenergic blockade of beta-receptors,” Research Communications in Chemical Pathology and Pharmacology, vol. 17, no. 1, pp. 157–164, 1977. View at Google Scholar
  9. Y. Imai, N. Watanabe, J. Hashimoto et al., “Muscle cramps and elevated serum creatine phosphokinase levels induced by β-adrenoceptor blockers,” European Journal of Clinical Pharmacology, vol. 48, no. 1, pp. 29–34, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Finsterer and E. Gelpi, “Mitochondrial disorder aggravated by propranolol,” Southern Medical Journal, vol. 99, no. 7, pp. 768–771, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Blessing and J. C. Walsh, “Myotonia precipitated by propranolol therapy,” The Lancet, vol. 1, no. 8002, pp. 73–74, 1977. View at Google Scholar · View at Scopus